Toyomasa Katagiri

Prof. Dr. Toyomasa Katagiri

Division of Genome Medicine, Institute for Genome Research, The University of Tokushima, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
KTKeisuke Taniuchi
Keisuke Taniuchi
HNHidewaki Nakagawa
Hidewaki Nakagawa
MHMasayo Hosokawa
Masayo Hosokawa
TNToru Nakamura
Toru Nakamura
HEHidetoshi Eguchi
Hidetoshi Eguchi
YNYusuke Nakamura
Yusuke Nakamura
P-Cadherin/CDH3 belongs to the family of classic cadherins that are engaged in various cellular activities including motility, invasion, and signaling of tumor cells, in addition to cell adhesion. However, the biological roles of P-cadherin itself are not fully characterized. Based on information derived from a previous genome-wide cDNA microarray analysis of microdissected pancreatic ductal adenocarcinoma (PDAC), we focused on P-cadherin as one of the genes most strongly overexpressed in the great majority of PDACs. To investigate the consequences of overexpression of P-cadherin in terms of pancreatic carcinogenesis and tumor progression, we used a P-cadherin–deficient PDAC cell line, Panc-1, to construct a cell line (Panc1-CDH3) that stably overexpressed P-cadherin. Induction of P-cadherin in Panc1-CDH3 increased the motility of the cancer cells, but a blocking antibody against P-cadherin suppressed the motility in vitro. Overexpression of P-cadherin was strongly associated with cytoplasmic accumulation of one of the catenins, p120ctn, and cadherin switching in PDAC cells. Moreover, P-cadherin–dependent activation of cell motility was associated with activation of Rho GTPases, Rac1 and Cdc42, through accumulation of p120ctn in cytoplasm and cadherin switching. These findings suggest that overexpression of P-cadherin is likely to be related to the biological aggressiveness of PDACs; blocking of P-cadherin activity or its associated signaling could be a novel therapeutic approach for treatment of aggressive pancreatic cancers.

18 December 2012 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
MKMasato Komatsu
Masato Komatsu
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
TMTaisuke Matsuo
Taisuke Matsuo
KKKazuma Kiyotani
Kazuma Kiyotani
YMYasuo Miyoshi
Yasuo Miyoshi
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Triple negative breast cancer (TNBC) has a poor outcome due to the lack of beneficial therapeutic targets. To clarify the molecular mechanisms involved in the carcinogenesis of TNBC and to identify target molecules for novel anticancer drugs, we analyzed the gene expression profiles of 30 TNBCs as well as 13 normal epithelial ductal cells that were purified by laser-microbeam microdissection. We identified 301 and 321 transcripts that were significantly upregulated and downregulated in TNBC, respectively. In particular, gene expression profile analyses of normal human vital organs allowed us to identify 104 cancer-specific genes, including those involved in breast carcinogenesis such as NEK2, PBK and MELK. Moreover, gene annotation enrichment analysis revealed prominent gene subsets involved in the cell cycle, especially mitosis. Therefore, we focused on cell cycle regulators, asp (abnormal spindle) homolog, microcephaly-associated (Drosophila) (ASPM) and centromere protein K (CENPK) as novel therapeutic targets for TNBC. Small-interfering RNA-mediated knockdown of their expression significantly attenuated TNBC cell viability due to G1 and G2/M cell cycle arrest. Our data will provide a better understanding of the carcinogenesis of TNBC and could contribute to the development of molecular targets as a treatment for TNBC patients.

14 July 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
YHYosuke Harada
Yosuke Harada
MKMitsugu Kanehira
Mitsugu Kanehira
YFYoshiko Fujisawa
Yoshiko Fujisawa
RTRyo Takata
Ryo Takata
TSTaro Shuin
Taro Shuin
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Bladder cancer is the second most common genitourinary cancer worldwide, yet its oncogenic origins remain poorly understood. The cancer-testis antigen DEPDC1 was shown recently to contribute to bladder cancer oncogenesis. In this study, we examined the biological functions of DEPDC1 and defined a potential therapeutic strategy to target this molecule. Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. Inhibiting this interaction with a cell-permeable peptide corresponding to the ZNF224-interacting domain in DEPDC1 induced apoptosis of bladder cancer cells in vitro and in vivo. By inhibiting DEPDC1-ZNF224 complex formation, this peptide triggered transcriptional activation of A20, a potent inhibitor of the NF-κB signaling pathway. Our findings indicate that the DEPDC1-ZNF224 complex is likely to play a critical role in bladder carcinogenesis. Cancer Res; 70(14); 5829–39. ©2010 AACR.

8 December 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
MKMasato Komatsu
Masato Komatsu
ETEtsu Tashiro
Etsu Tashiro
MIMasaya Imoto
Masaya Imoto
HOHiroyuki Osada
Hiroyuki Osada
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Xanthohumol (XN) is a natural anticancer compound that inhibits the proliferation of oestrogen receptor-α (ERα)-positive breast cancer cells. However, the precise mechanism of the antitumour effects of XN on oestrogen (E2)-dependent cell growth, and especially its direct target molecule(s), remain(s) largely unknown. Here, we focus on whether XN directly binds to the tumour suppressor protein prohibitin 2 (PHB2), forming a novel natural antitumour compound targeting the BIG3-PHB2 complex and acting as a pivotal modulator of E2/ERα signalling in breast cancer cells. XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERα. This event led to the complete suppression of the E2-signalling pathways and ERα-positive breast cancer cell growth both in vitro and in vivo, but did not suppress the growth of normal mammary epithelial cells. Our findings suggest that XN may be a promising natural compound to suppress the growth of luminal-type breast cancer.

20 September 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYTetsuro Yoshimaru
Tetsuro Yoshimaru
MKMasato Komatsu
Masato Komatsu
TMTaisuke Matsuo
Taisuke Matsuo
YCYi-An Chen
Yi-An Chen
YMYoichi Murakami
Yoichi Murakami
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
The acquisition of endocrine resistance is a common obstacle in endocrine therapy of patients with oestrogen receptor-α (ERα)-positive breast tumours. We previously demonstrated that the BIG3–PHB2 complex has a crucial role in the modulation of oestrogen/ERα signalling in breast cancer cells. Here we report a cell-permeable peptide inhibitor, called ERAP, that regulates multiple ERα-signalling pathways associated with tamoxifen resistance in breast cancer cells by inhibiting the interaction between BIG3 and PHB2. Intrinsic PHB2 released from BIG3 by ERAP directly binds to both nuclear- and membrane-associated ERα, which leads to the inhibition of multiple ERα-signalling pathways, including genomic and non-genomic ERα activation and ERα phosphorylation, and the growth of ERα-positive breast cancer cells both in vitro and in vivo. More importantly, ERAP treatment suppresses tamoxifen resistance and enhances tamoxifen responsiveness in ERα-positive breast cancer cells. These findings suggest inhibiting the interaction between BIG3 and PHB2 may be a new therapeutic strategy for the treatment of luminal-type breast cancer.

10 July 2009 in Cancer Science
Verified
Journal Article
Open access
PDF file
MLMeng‐Lay Lin
Meng‐Lay Lin
CFChikako Fukukawa
Chikako Fukukawa
JPJae‐Hyun Park
Jae‐Hyun Park
KNKie Naito
Kie Naito
KKKyoko Kijima
Kyoko Kijima
Toyomasa KatagiriToyomasa Katagiri
Toyomasa Katagiri
Through analysis of the detailed genome‐wide gene expression profiles of 81 breast tumors, we identified a novel gene, G‐patch domain containing 2 (GPATCH2), that was overexpressed in the great majority of breast cancer cases. Treatment of breast cancer cells MCF‐7 and T47D with siRNA against GPATCH2 effectively suppressed its expression, and resulted in the growth suppression of cancer cells, suggesting its essential role in breast cancer cell growth. We found an interaction of GPATCH2 protein with hPrp43, an RNA‐dependent ATPase. Their interaction could significantly enhance the ATPase activity of hPrp43 and induce a growth‐promoting effect on mammalian cells. Because northern blot analyses of normal human organs implied GPATCH2 to be a novel cancer/testis antigen, targeting GPATCH2 or inhibition of the interaction between GPATCH2 and hPrp43 could be a promising novel therapeutic strategy of breast cancer. (Cancer Sci 2009)